Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 81 | 2024 | 5432 | 5.210 |
Why?
|
Lung Neoplasms | 105 | 2025 | 13586 | 4.400 |
Why?
|
Proto-Oncogene Proteins c-met | 12 | 2024 | 564 | 2.320 |
Why?
|
Small Cell Lung Carcinoma | 11 | 2025 | 454 | 1.870 |
Why?
|
Immunoconjugates | 5 | 2024 | 975 | 1.530 |
Why?
|
Exons | 8 | 2024 | 2394 | 1.450 |
Why?
|
Adenocarcinoma | 31 | 2021 | 6395 | 1.280 |
Why?
|
Triazines | 4 | 2024 | 311 | 1.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 26 | 2025 | 11878 | 1.260 |
Why?
|
Antineoplastic Agents | 29 | 2025 | 13676 | 1.210 |
Why?
|
Protein Kinase Inhibitors | 26 | 2024 | 5703 | 1.100 |
Why?
|
Polymorphism, Genetic | 16 | 2014 | 4249 | 0.930 |
Why?
|
Drug Resistance, Neoplasm | 16 | 2024 | 5341 | 0.920 |
Why?
|
Esophageal Neoplasms | 19 | 2020 | 1668 | 0.890 |
Why?
|
Benzamides | 4 | 2024 | 1379 | 0.890 |
Why?
|
Sulfonamides | 3 | 2024 | 1982 | 0.770 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 10 | 2024 | 1767 | 0.750 |
Why?
|
Camptothecin | 3 | 2024 | 600 | 0.720 |
Why?
|
Mutation | 38 | 2024 | 30238 | 0.710 |
Why?
|
Salvage Therapy | 4 | 2019 | 1273 | 0.660 |
Why?
|
Pyridines | 9 | 2022 | 2894 | 0.650 |
Why?
|
Niacinamide | 2 | 2018 | 418 | 0.650 |
Why?
|
Oximes | 1 | 2020 | 303 | 0.610 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 6 | 2013 | 362 | 0.590 |
Why?
|
Quinoxalines | 1 | 2018 | 297 | 0.540 |
Why?
|
Pyrazoles | 8 | 2022 | 2028 | 0.530 |
Why?
|
Acetonitriles | 5 | 2023 | 55 | 0.530 |
Why?
|
Carcinoma, Large Cell | 3 | 2014 | 114 | 0.520 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2019 | 259 | 0.520 |
Why?
|
Vascular Endothelial Growth Factor A | 6 | 2015 | 3514 | 0.520 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 637 | 0.510 |
Why?
|
Neoplasm Staging | 29 | 2024 | 11244 | 0.500 |
Why?
|
Imidazoles | 4 | 2024 | 1169 | 0.500 |
Why?
|
Neoplasm Recurrence, Local | 15 | 2025 | 9419 | 0.490 |
Why?
|
Aged, 80 and over | 59 | 2025 | 59629 | 0.460 |
Why?
|
Pyrimidinones | 4 | 2024 | 386 | 0.460 |
Why?
|
Gene Amplification | 3 | 2020 | 1095 | 0.440 |
Why?
|
Piperazines | 8 | 2025 | 2554 | 0.440 |
Why?
|
Aged | 93 | 2025 | 171504 | 0.420 |
Why?
|
Maximum Tolerated Dose | 7 | 2025 | 899 | 0.410 |
Why?
|
Middle Aged | 94 | 2025 | 223492 | 0.390 |
Why?
|
Angiogenesis Inhibitors | 4 | 2022 | 2056 | 0.380 |
Why?
|
Pyridones | 4 | 2024 | 819 | 0.380 |
Why?
|
Carcinoma, Squamous Cell | 7 | 2018 | 4058 | 0.380 |
Why?
|
Polymorphism, Single Nucleotide | 20 | 2015 | 16045 | 0.370 |
Why?
|
Humans | 150 | 2025 | 768166 | 0.370 |
Why?
|
Sarcoma | 1 | 2022 | 1806 | 0.370 |
Why?
|
Pyrimidines | 9 | 2022 | 3048 | 0.340 |
Why?
|
Antibodies, Monoclonal | 8 | 2021 | 9263 | 0.340 |
Why?
|
Bone Neoplasms | 1 | 2022 | 2565 | 0.340 |
Why?
|
Neoplasms | 12 | 2025 | 22371 | 0.330 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2018 | 2062 | 0.330 |
Why?
|
Neovascularization, Pathologic | 4 | 2024 | 2631 | 0.330 |
Why?
|
Female | 105 | 2025 | 397192 | 0.320 |
Why?
|
Anilides | 2 | 2022 | 413 | 0.320 |
Why?
|
Receptors, Calcitriol | 2 | 2008 | 361 | 0.320 |
Why?
|
Adult | 73 | 2025 | 223646 | 0.310 |
Why?
|
Matrix Metalloproteinases | 2 | 2012 | 393 | 0.310 |
Why?
|
Male | 98 | 2025 | 364719 | 0.300 |
Why?
|
Smoking | 13 | 2017 | 9092 | 0.300 |
Why?
|
Lactams, Macrocyclic | 3 | 2022 | 319 | 0.290 |
Why?
|
Aniline Compounds | 3 | 2024 | 1094 | 0.280 |
Why?
|
Disease-Free Survival | 19 | 2020 | 6847 | 0.270 |
Why?
|
Prognosis | 29 | 2024 | 30010 | 0.270 |
Why?
|
Acrylamides | 3 | 2018 | 261 | 0.270 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2020 | 423 | 0.260 |
Why?
|
Survival Rate | 16 | 2019 | 12840 | 0.260 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2018 | 3556 | 0.260 |
Why?
|
Brain Neoplasms | 7 | 2024 | 9118 | 0.260 |
Why?
|
Gastroesophageal Reflux | 7 | 2013 | 836 | 0.260 |
Why?
|
Genetic Markers | 1 | 2012 | 2603 | 0.250 |
Why?
|
Methionine Adenosyltransferase | 1 | 2025 | 16 | 0.250 |
Why?
|
Genotype | 20 | 2014 | 13045 | 0.240 |
Why?
|
Benzimidazoles | 2 | 2021 | 864 | 0.230 |
Why?
|
GTP Phosphohydrolases | 3 | 2024 | 525 | 0.230 |
Why?
|
bcl-X Protein | 2 | 2024 | 412 | 0.230 |
Why?
|
Platinum Compounds | 2 | 2017 | 95 | 0.220 |
Why?
|
Quinazolines | 5 | 2016 | 1373 | 0.200 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2024 | 330 | 0.200 |
Why?
|
Pharmacy | 1 | 2023 | 92 | 0.190 |
Why?
|
Trophoblasts | 1 | 2023 | 223 | 0.190 |
Why?
|
Fibroblast Growth Factor 7 | 1 | 2021 | 59 | 0.190 |
Why?
|
Survival Analysis | 10 | 2019 | 10101 | 0.180 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 3 | 2010 | 105 | 0.180 |
Why?
|
Cell Adhesion Molecules | 2 | 2017 | 1613 | 0.180 |
Why?
|
Neoplasms, Second Primary | 2 | 2023 | 1061 | 0.180 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 10760 | 0.180 |
Why?
|
Ameloblastoma | 1 | 2021 | 42 | 0.180 |
Why?
|
Neoplasm Metastasis | 6 | 2024 | 4912 | 0.180 |
Why?
|
Jaw Neoplasms | 1 | 2021 | 71 | 0.180 |
Why?
|
ras Proteins | 3 | 2014 | 1058 | 0.180 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2024 | 2059 | 0.170 |
Why?
|
Oncogene Proteins, Fusion | 5 | 2018 | 1613 | 0.170 |
Why?
|
Hepatocyte Growth Factor | 1 | 2021 | 268 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 12 | 2020 | 6526 | 0.170 |
Why?
|
Gene Dosage | 3 | 2020 | 1219 | 0.170 |
Why?
|
Treatment Outcome | 26 | 2025 | 65371 | 0.170 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2020 | 93 | 0.170 |
Why?
|
Stomach Neoplasms | 2 | 2020 | 1481 | 0.170 |
Why?
|
Exanthema | 2 | 2023 | 503 | 0.160 |
Why?
|
Melanoma | 3 | 2023 | 5706 | 0.160 |
Why?
|
Antigens, Neoplasm | 2 | 2017 | 1997 | 0.160 |
Why?
|
Receptor, Adenosine A2A | 1 | 2019 | 129 | 0.160 |
Why?
|
Codon | 1 | 2021 | 599 | 0.160 |
Why?
|
Point Mutation | 1 | 2024 | 1596 | 0.160 |
Why?
|
Cisplatin | 4 | 2013 | 1660 | 0.160 |
Why?
|
Antigens, Surface | 1 | 2023 | 1617 | 0.160 |
Why?
|
Resorcinols | 1 | 2018 | 41 | 0.160 |
Why?
|
Cough | 1 | 2022 | 598 | 0.160 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 109 | 0.150 |
Why?
|
Endonucleases | 3 | 2010 | 371 | 0.150 |
Why?
|
Vitamin D | 3 | 2008 | 3311 | 0.150 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2020 | 331 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 354 | 0.150 |
Why?
|
Carboplatin | 3 | 2018 | 797 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 212 | 0.140 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2015 | 2954 | 0.140 |
Why?
|
Central Nervous System | 1 | 2025 | 1346 | 0.140 |
Why?
|
Isoxazoles | 1 | 2018 | 233 | 0.140 |
Why?
|
Genetic Variation | 1 | 2012 | 6611 | 0.140 |
Why?
|
Combined Modality Therapy | 2 | 2023 | 8542 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2018 | 228 | 0.140 |
Why?
|
DNA, Neoplasm | 4 | 2015 | 1744 | 0.140 |
Why?
|
Aminopyridines | 4 | 2024 | 580 | 0.130 |
Why?
|
In Situ Hybridization, Fluorescence | 4 | 2020 | 2521 | 0.130 |
Why?
|
Breast Neoplasms | 1 | 2024 | 21206 | 0.130 |
Why?
|
Receptor, erbB-2 | 3 | 2024 | 2603 | 0.130 |
Why?
|
Proportional Hazards Models | 11 | 2017 | 12543 | 0.130 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 4860 | 0.130 |
Why?
|
Gene Fusion | 1 | 2019 | 356 | 0.130 |
Why?
|
Mutagenesis, Insertional | 1 | 2018 | 661 | 0.130 |
Why?
|
Apoptosis | 5 | 2014 | 9523 | 0.130 |
Why?
|
Guanine | 2 | 2014 | 280 | 0.120 |
Why?
|
Glutamates | 2 | 2014 | 385 | 0.120 |
Why?
|
Central Nervous System Neoplasms | 1 | 2023 | 928 | 0.120 |
Why?
|
Follow-Up Studies | 13 | 2024 | 39348 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 348 | 0.120 |
Why?
|
Pharmacogenetics | 2 | 2009 | 683 | 0.120 |
Why?
|
Triazoles | 1 | 2020 | 904 | 0.110 |
Why?
|
Lactams | 3 | 2022 | 159 | 0.110 |
Why?
|
HLA-D Antigens | 1 | 2014 | 130 | 0.110 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 94 | 0.110 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2017 | 496 | 0.110 |
Why?
|
Biopsy | 4 | 2021 | 6793 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2020 | 2457 | 0.100 |
Why?
|
Neoplasm Proteins | 2 | 2017 | 3603 | 0.100 |
Why?
|
Matrix Metalloproteinase 12 | 2 | 2009 | 44 | 0.100 |
Why?
|
Carcinoma, Ductal | 1 | 2012 | 97 | 0.100 |
Why?
|
Terminal Care | 2 | 2016 | 1770 | 0.100 |
Why?
|
Albumins | 1 | 2015 | 577 | 0.100 |
Why?
|
Molecular Targeted Therapy | 4 | 2017 | 2830 | 0.100 |
Why?
|
Colorectal Neoplasms | 3 | 2021 | 6974 | 0.100 |
Why?
|
Administration, Oral | 1 | 2020 | 4030 | 0.100 |
Why?
|
Matrix Metalloproteinase 1 | 2 | 2009 | 147 | 0.100 |
Why?
|
Matrix Metalloproteinase 3 | 2 | 2009 | 139 | 0.100 |
Why?
|
Pneumonectomy | 2 | 2018 | 1156 | 0.090 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2015 | 526 | 0.090 |
Why?
|
Gene Frequency | 5 | 2009 | 3623 | 0.090 |
Why?
|
Radiation Pneumonitis | 1 | 2011 | 100 | 0.090 |
Why?
|
Angiogenic Proteins | 1 | 2011 | 101 | 0.090 |
Why?
|
Gossypol | 1 | 2010 | 23 | 0.090 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2016 | 1627 | 0.090 |
Why?
|
MAP Kinase Signaling System | 2 | 2017 | 1494 | 0.090 |
Why?
|
Gene Rearrangement | 1 | 2016 | 1146 | 0.090 |
Why?
|
Medical Oncology | 2 | 2022 | 2346 | 0.090 |
Why?
|
Remission Induction | 2 | 2014 | 2410 | 0.090 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 276 | 0.090 |
Why?
|
Topotecan | 1 | 2010 | 131 | 0.090 |
Why?
|
Haplotypes | 4 | 2009 | 2722 | 0.090 |
Why?
|
Phosphatidylinositol 3-Kinases | 5 | 2023 | 2885 | 0.080 |
Why?
|
Phthalazines | 2 | 2025 | 397 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 3 | 2023 | 4528 | 0.080 |
Why?
|
Radiology | 1 | 2023 | 2104 | 0.080 |
Why?
|
DNA Repair | 2 | 2009 | 2050 | 0.080 |
Why?
|
Genes, Neoplasm | 1 | 2011 | 371 | 0.080 |
Why?
|
Tissue Distribution | 3 | 2020 | 2300 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2019 | 3671 | 0.080 |
Why?
|
Immunohistochemistry | 3 | 2014 | 11095 | 0.080 |
Why?
|
Immunotherapy | 2 | 2023 | 4755 | 0.080 |
Why?
|
Sirolimus | 2 | 2013 | 1540 | 0.080 |
Why?
|
Salivary Gland Neoplasms | 1 | 2012 | 306 | 0.080 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 89 | 0.080 |
Why?
|
Body Mass Index | 4 | 2017 | 13053 | 0.080 |
Why?
|
Hydroxychloroquine | 1 | 2012 | 426 | 0.080 |
Why?
|
Clinical Trials as Topic | 4 | 2013 | 8054 | 0.080 |
Why?
|
Pancreatic Neoplasms | 2 | 2021 | 5446 | 0.080 |
Why?
|
Radiotherapy | 2 | 2013 | 1502 | 0.080 |
Why?
|
Cohort Studies | 11 | 2020 | 41754 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2021 | 8647 | 0.070 |
Why?
|
Membrane Proteins | 2 | 2023 | 7876 | 0.070 |
Why?
|
Pyrroles | 1 | 2014 | 1124 | 0.070 |
Why?
|
Alleles | 5 | 2012 | 6894 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1406 | 0.070 |
Why?
|
Paclitaxel | 1 | 2015 | 1733 | 0.070 |
Why?
|
Deoxycytidine | 2 | 2009 | 887 | 0.070 |
Why?
|
beta Catenin | 1 | 2012 | 1047 | 0.070 |
Why?
|
Quality of Life | 5 | 2022 | 13490 | 0.070 |
Why?
|
Cyclin D1 | 1 | 2009 | 453 | 0.070 |
Why?
|
Organoplatinum Compounds | 1 | 2008 | 408 | 0.070 |
Why?
|
Case-Control Studies | 12 | 2012 | 22291 | 0.070 |
Why?
|
Palliative Care | 2 | 2012 | 3643 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 9 | 2012 | 18065 | 0.070 |
Why?
|
Epidermal Growth Factor | 1 | 2009 | 697 | 0.070 |
Why?
|
Thiazoles | 1 | 2013 | 1542 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2019 | 3611 | 0.060 |
Why?
|
Genetic Testing | 1 | 2019 | 3591 | 0.060 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2008 | 461 | 0.060 |
Why?
|
Self Report | 1 | 2017 | 3773 | 0.060 |
Why?
|
Neoplasm Invasiveness | 4 | 2015 | 3620 | 0.060 |
Why?
|
Indoles | 1 | 2014 | 1836 | 0.060 |
Why?
|
Retrospective Studies | 8 | 2023 | 81762 | 0.060 |
Why?
|
Cell Line, Tumor | 5 | 2024 | 17140 | 0.060 |
Why?
|
Helicobacter pylori | 1 | 2008 | 380 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2019 | 3187 | 0.060 |
Why?
|
Young Adult | 13 | 2024 | 60066 | 0.060 |
Why?
|
Helicobacter Infections | 1 | 2008 | 390 | 0.060 |
Why?
|
DNA-Binding Proteins | 3 | 2010 | 9615 | 0.060 |
Why?
|
S-Adenosylmethionine | 1 | 2025 | 219 | 0.050 |
Why?
|
Data Collection | 1 | 2012 | 3327 | 0.050 |
Why?
|
Documentation | 1 | 2009 | 917 | 0.050 |
Why?
|
Prospective Studies | 8 | 2021 | 54926 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2009 | 2433 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 2019 | 4282 | 0.050 |
Why?
|
Carcinoma, Papillary | 1 | 2008 | 793 | 0.050 |
Why?
|
Odds Ratio | 6 | 2012 | 9669 | 0.050 |
Why?
|
Risk Factors | 15 | 2017 | 74944 | 0.050 |
Why?
|
Confidence Intervals | 3 | 2014 | 2923 | 0.050 |
Why?
|
Advance Care Planning | 1 | 2009 | 698 | 0.050 |
Why?
|
Survivors | 1 | 2012 | 2381 | 0.050 |
Why?
|
Genomics | 1 | 2018 | 5926 | 0.050 |
Why?
|
Age Factors | 4 | 2013 | 18412 | 0.050 |
Why?
|
Caspase 7 | 2 | 2011 | 51 | 0.050 |
Why?
|
Genetic Association Studies | 1 | 2010 | 2744 | 0.040 |
Why?
|
Genome-Wide Association Study | 4 | 2014 | 12795 | 0.040 |
Why?
|
Tobacco Smoke Pollution | 1 | 2006 | 828 | 0.040 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2023 | 381 | 0.040 |
Why?
|
DNA Mutational Analysis | 3 | 2015 | 4120 | 0.040 |
Why?
|
Diamines | 1 | 2020 | 60 | 0.040 |
Why?
|
Time Factors | 7 | 2021 | 40218 | 0.040 |
Why?
|
Promoter Regions, Genetic | 2 | 2008 | 5797 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2015 | 905 | 0.040 |
Why?
|
Signal Transduction | 4 | 2021 | 23645 | 0.040 |
Why?
|
Leucovorin | 1 | 2021 | 643 | 0.040 |
Why?
|
Enzyme Inhibitors | 2 | 2025 | 3728 | 0.040 |
Why?
|
Appendiceal Neoplasms | 1 | 2021 | 155 | 0.040 |
Why?
|
Depressive Disorder | 1 | 2012 | 3721 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 3948 | 0.040 |
Why?
|
Pilot Projects | 3 | 2021 | 8741 | 0.040 |
Why?
|
Furans | 1 | 2019 | 199 | 0.040 |
Why?
|
Ambulatory Care | 1 | 2009 | 2783 | 0.040 |
Why?
|
Ethylnitrosourea | 1 | 2018 | 50 | 0.040 |
Why?
|
Mice | 6 | 2024 | 82029 | 0.040 |
Why?
|
MicroRNAs | 1 | 2014 | 3803 | 0.040 |
Why?
|
Massachusetts | 3 | 2020 | 8890 | 0.040 |
Why?
|
Esophagogastric Junction | 1 | 2020 | 351 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 854 | 0.040 |
Why?
|
Polymerase Chain Reaction | 3 | 2014 | 6082 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 860 | 0.040 |
Why?
|
Nausea | 1 | 2020 | 682 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 565 | 0.040 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2017 | 108 | 0.030 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2017 | 70 | 0.030 |
Why?
|
Research Design | 1 | 2012 | 6211 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 876 | 0.030 |
Why?
|
Capsules | 1 | 2017 | 193 | 0.030 |
Why?
|
Tablets | 1 | 2017 | 149 | 0.030 |
Why?
|
Edema | 1 | 2020 | 765 | 0.030 |
Why?
|
Logistic Models | 4 | 2012 | 13290 | 0.030 |
Why?
|
Biological Availability | 1 | 2017 | 389 | 0.030 |
Why?
|
Fluorouracil | 1 | 2021 | 1652 | 0.030 |
Why?
|
Drug Compounding | 1 | 2017 | 241 | 0.030 |
Why?
|
Vesicle-Associated Membrane Protein 2 | 1 | 2015 | 17 | 0.030 |
Why?
|
Disease Progression | 3 | 2019 | 13671 | 0.030 |
Why?
|
Cranial Irradiation | 1 | 2018 | 393 | 0.030 |
Why?
|
Oncogene Fusion | 1 | 2015 | 84 | 0.030 |
Why?
|
Tropomyosin | 1 | 2015 | 106 | 0.030 |
Why?
|
Lung | 1 | 2014 | 10099 | 0.030 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2015 | 318 | 0.030 |
Why?
|
Neuregulin-1 | 1 | 2015 | 136 | 0.030 |
Why?
|
Receptor, trkA | 1 | 2015 | 159 | 0.030 |
Why?
|
Perfusion Imaging | 1 | 2016 | 195 | 0.030 |
Why?
|
Thyroid Neoplasms | 1 | 2008 | 2360 | 0.030 |
Why?
|
Smoking Cessation | 1 | 2006 | 2085 | 0.030 |
Why?
|
Obesity | 1 | 2017 | 13090 | 0.030 |
Why?
|
Inflammation | 1 | 2014 | 10873 | 0.030 |
Why?
|
Risk | 3 | 2011 | 9613 | 0.030 |
Why?
|
Dietary Supplements | 1 | 2007 | 3445 | 0.030 |
Why?
|
Sulfones | 1 | 2016 | 448 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2021 | 1996 | 0.030 |
Why?
|
Depressive Disorder, Major | 1 | 2011 | 4818 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1837 | 0.030 |
Why?
|
Sex Factors | 3 | 2013 | 10632 | 0.030 |
Why?
|
Protein Conformation | 1 | 2021 | 3956 | 0.030 |
Why?
|
Animals | 6 | 2024 | 169246 | 0.030 |
Why?
|
Reference Values | 2 | 2012 | 4938 | 0.030 |
Why?
|
Boston | 3 | 2014 | 9374 | 0.030 |
Why?
|
Nuclear Proteins | 2 | 2023 | 5804 | 0.030 |
Why?
|
Neutropenia | 1 | 2018 | 892 | 0.030 |
Why?
|
Texas | 1 | 2014 | 410 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 1327 | 0.030 |
Why?
|
Area Under Curve | 1 | 2017 | 1643 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2627 | 0.030 |
Why?
|
Up-Regulation | 1 | 2021 | 4146 | 0.030 |
Why?
|
Etoposide | 1 | 2013 | 639 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2017 | 5315 | 0.020 |
Why?
|
Risk Assessment | 5 | 2013 | 24315 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2009 | 4887 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2018 | 2916 | 0.020 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2012 | 300 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2015 | 1441 | 0.020 |
Why?
|
Adolescent | 4 | 2023 | 89169 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2017 | 2107 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 2048 | 0.020 |
Why?
|
Pulmonary Alveoli | 1 | 2013 | 665 | 0.020 |
Why?
|
Caspase 9 | 1 | 2010 | 184 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2011 | 257 | 0.020 |
Why?
|
Terminally Ill | 1 | 2012 | 240 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2907 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2018 | 10399 | 0.020 |
Why?
|
Organ Specificity | 1 | 2014 | 1968 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2014 | 1151 | 0.020 |
Why?
|
Pulmonary Emphysema | 1 | 2014 | 689 | 0.020 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2009 | 323 | 0.020 |
Why?
|
Fas Ligand Protein | 1 | 2008 | 216 | 0.020 |
Why?
|
Thyroglobulin | 1 | 2008 | 111 | 0.020 |
Why?
|
Norway | 1 | 2009 | 501 | 0.020 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2009 | 387 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2862 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2012 | 812 | 0.020 |
Why?
|
Mice, Nude | 1 | 2014 | 3623 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2012 | 1737 | 0.020 |
Why?
|
Carcinoma, Medullary | 1 | 2008 | 116 | 0.020 |
Why?
|
Resuscitation Orders | 1 | 2009 | 271 | 0.020 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2009 | 452 | 0.020 |
Why?
|
Proline | 1 | 2009 | 455 | 0.020 |
Why?
|
Factor Analysis, Statistical | 1 | 2010 | 1001 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3568 | 0.020 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2009 | 458 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2011 | 1062 | 0.020 |
Why?
|
Predictive Value of Tests | 3 | 2009 | 15454 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2010 | 994 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20227 | 0.020 |
Why?
|
Genes, ras | 1 | 2009 | 663 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 620 | 0.020 |
Why?
|
Adenoma, Oxyphilic | 1 | 2008 | 152 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2015 | 1388 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5777 | 0.020 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2009 | 290 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3968 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 789 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2012 | 1474 | 0.020 |
Why?
|
Oncogenes | 1 | 2011 | 1234 | 0.020 |
Why?
|
Arginine | 1 | 2009 | 932 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2008 | 640 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2012 | 9538 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5367 | 0.010 |
Why?
|
Phenotype | 2 | 2014 | 16726 | 0.010 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2008 | 326 | 0.010 |
Why?
|
Cadherins | 1 | 2009 | 905 | 0.010 |
Why?
|
Introns | 1 | 2007 | 966 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2013 | 2885 | 0.010 |
Why?
|
Age of Onset | 1 | 2011 | 3347 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3436 | 0.010 |
Why?
|
Transcription Factors | 1 | 2023 | 12168 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2018 | 20760 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2008 | 879 | 0.010 |
Why?
|
Radiation Dosage | 1 | 2011 | 1967 | 0.010 |
Why?
|
Interleukin-1beta | 1 | 2008 | 1027 | 0.010 |
Why?
|
Homozygote | 1 | 2007 | 1779 | 0.010 |
Why?
|
Genome, Human | 1 | 2015 | 4446 | 0.010 |
Why?
|
Seasons | 1 | 2007 | 1524 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2009 | 3800 | 0.010 |
Why?
|
Mitochondria | 1 | 2014 | 3681 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2016 | 10474 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2008 | 2741 | 0.010 |
Why?
|
RNA-Binding Proteins | 1 | 2009 | 1890 | 0.010 |
Why?
|
Diarrhea | 1 | 2007 | 1320 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12077 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4206 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2016 | 6669 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2016 | 9015 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2009 | 2892 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18349 | 0.010 |
Why?
|
Family | 1 | 2009 | 3209 | 0.010 |
Why?
|
United States | 2 | 2018 | 73039 | 0.010 |
Why?
|
Chronic Disease | 1 | 2012 | 9384 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2008 | 2650 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10590 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36743 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2009 | 14783 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2014 | 26379 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2009 | 11669 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15948 | 0.010 |
Why?
|
Diet | 1 | 2007 | 8089 | 0.000 |
Why?
|
Algorithms | 1 | 2008 | 14164 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2012 | 15662 | 0.000 |
Why?
|